| 24 September 2022 | Comparative adherence and persistence of single- and multiple-inhaler triple therapies among patients with chronic obstructive pulmonary disease in an English real-world primary care setting
| Halpin, DMG; Rothnie, KJ; Banks, V; et al. |
| 20 July 2022 | Comparative efficacy of Umeclidinium/Vilanterol versus other bronchodilators for the treatment of chronic obstructive pulmonary disease: A network meta-analysis
| Ismaila, AS; Haeussler, K; Czira, A; et al. |
| 2 September 2022 | Correction to: Comparative efficacy of Umeclidinium/Vilanterol versus other bronchodilators for the treatment of chronic obstructive pulmonary disease: A network meta-analysis.
| Ismaila, AS; Haeussler, K; Czira, A; et al. |
| 25 October 2022 | Cost-effectiveness of single- versus multiple-inhaler triple therapy in a UK COPD population: The INTREPID trial
| Halpin, DMG; Kendall, R; Shukla, S; et al. |
| 17 July 2022 | Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy compared with other therapies for the treatment of COPD: A network meta-analysis
| Ismaila, AS; Haeussler, K; Czira, A; et al. |
| 1 April 2023 | A response to: Letter to the editor regarding "Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy compared with other therapies for the treatment of COPD: A network meta-analysis"
| Ismaila, AS; Haeussler, K; Malmenäs, M; et al. |
| 25 July 2022 | Single-inhaler triple therapy in patients with advanced COPD: Bayesian modeling of the healthcare resource utilization data and associated costs from the IMPACT trial
| Gabrio, A; Gunsoy, NB; Baio, G; et al. |
